Table 3.
Univariate and multivariate analysis of factors associated with DFS and OS
| Variables | Median DFS, months | Univariate p | Multivariate p | HR (95% CI) | Median OS, months | Univariate p | Multivariate p | HR (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Age | 0.366 | 0.058 | 0.877 | |||||
| » 50 years | 68.0 | |||||||
| ≤ 50 years | 87.0 | |||||||
| Menopausal status | 0.135 | 0.006* | 0.019* | 0.641 (0.442–0.929) | ||||
| Premenopausal | 93.0 | |||||||
| Postmenopausal | 66.0 | |||||||
| Histological type | 0.804 | 0.737 | ||||||
| ER status | 0.394 | 0.109 | ||||||
| PgR status | 0.003* | 0.026* | 0.621 (0.408–0.943) | 0.001* | 0.001* | 0.527 (0.364–0.762) | ||
| Negative | 32.0 | 66.0 | ||||||
| Positive | 53.0 | 104.0 | ||||||
| HER2 status | 0.013* | 0.813 | 0.037* | 0.103 | ||||
| Negative | 53.0 | 84.0 | ||||||
| Positive | 35.0 | 60.0 | ||||||
| T stage | 0.859 | 0.835 | ||||||
| Grade | 0.293 | 0.095 | ||||||
| Time of diagnosis | 0.040* | 0.051 | 0.709 (0.502–1.001) | 0.620 | ||||
| Before June 2007 | 38.0 | |||||||
| After June 2007 | 69.0 | |||||||
| Lymph node ratio | 0.006* | 0.010* | 1.530 (1.105–2.120) | 0.010* | 0.012* | 1.611 (1.108–2.341) | ||
| ≤ 0.75 | 67.0 | 93.0 | ||||||
| » 0.75 | 40.0 | 70.0 | ||||||
| Subgroups | 0.034* | 0.054 | 0.016* | 0.377 | ||||
| HR+/HER2– | 53.0 | 87.0 | ||||||
| HR+/HER2+ | 38.0 | 0.028* | 1.561 (1.050–2.320) | 60.0 | ||||
| HR–/HER2+ | 28.0 | 0.189 | 51.0 | |||||
| TN | 101.0 | 0.536 | 67.0 |
DFS = Disease-free survival, OS = overall survival, HR = hazard ratio, ER = estrogen receptor, PgR = progesterone receptor, HER2 = human epithelial growth factor receptor 2, HR = hormone receptor, TN = triple negative.
*
p < 0.05.